Sign in
AKRO Stock Price, Chart, Stats & News
Akero Therapeutics, Inc.
Save
4.50B
Market cap
–
Current P/E
–
Forward P/E
AKRO chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -29.12% |
ROE | -30.68% |
D/E | 0.00x |
Interest coverage ratio | -71.46x |
AKRO valuation
P/E | – |
P/S | – |
P/B | 4.68x |
P/CF | -17.91x |
P/FCF | -17.98x |
P/OCF | -17.91x |
PEG | -9.69x |
EV multiple | -16.22x |
About
Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21.
Similar securities
Based on sector and market capitalization
Report issue